ATB Therapeutics (“ATB” or the “Company”), a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, today announced the appointment of Mark Throsby, ...
EDMONTON, AB, Dec. 4, 2025 /CNW/ - ATB Financial's Board of Directors announced today that Chris Turchansky will be the company's next President and CEO. The Board's thorough selection process ...
Mark Throsby has served as Executive Chairman and Chief Scientific Officer since 2024, during which time he supported the Company’s growth, including the successful closing of its Series A financing, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results